Lu Guo

2019-01-09 T |T

Name: Lu Guo

Professional Title: Assistant professor
Office: Jingcheng Building
Research Interests: Bacteria drug resistance
Education/Training: 
2016 Ph. D. in Genetics, Lanzhou University
2006 M.S. in Biochemistry and Molecular biology, Lanzhou University
2003 B.S in Clinical medicine, Lanzhou University
Awards & Honors: 
2017  the second prize of the Lanzhou University Basic Medical School Teaching Contest.
2015  the third prize of the Lanzhou University Basic Medical School Teaching Contest.
Projects:
Hosted 2 projects of the Fundamental Research Funds for the Central Universities and participated in 4 NSFC.
1.  The Fundamental Research Funds for the Central Universities, The research on    mechanisms of persister in Shigella flexneri, 2018-2019£¬Project Leader.
2.  The Fundamental Research Funds for the Central Universities, Neoadjuvant chemotherapeutic sensitivity associated with genetic polymorphisms in the PI3K/Akt pathway in cervical cancer, 2015-2016, Project Leader.
3.  The national natural science foundation of China, The mechanism of chaperon SurA in E.coli, 2018-2019, Project Member.
4.  The national natural science foundation of China, Inhibition of glycolytic enzyme ENO1 activity combined with IL-28B downregulation of regulatory T cells for cervical cancer treatment, 2016-2019, Project Member.
5.  The national natural science foundation of China, The mechanism of  transcription factor NWMN_0037 regulating the formation, virulence and metabolism of the persister in S. aureus, 2016-2019, Project Member.
6.  The national natural science foundation of China,  The molecular mechanism of NWMN_0037 on the formation and virulence of Staphylococcus aureus Newman, 2015, Project Member.
 
 
Publications:
1. Guo L, Zhang C, Zhu J, Yang Y, Lan J, Su G and Xie X,  Proteomic identification of predictive tissue biomarkers of sensitive to neoadjuvant chemotherapy in squamous cervical cancer. Life Sci, 2016, 151:102-108.
2. Guo L, Wu H, Zhu J, Zhang C, Ma J, Lan J and Xie X, Genetic variations in the PI3K/AKT pathway predict platinum-based neoadjuvant chemotherapeutic sensitivity in squamous cervical cancer. Life Sci, 2015, 143:217-24.